FeUP 210 FC Tablet

About FeUP 210 FC 1000 mg Tablet

FeUP 210 FC is a tablet made by Advanced Chemical Industries PLC that contains Ferric Citrate at a strength of 1000 mg. It belongs to the oral iron preparations group of medicines.

There are 4 brands of Ferric Citrate listed in Bangladesh. The lowest listed price is Revocit 1000 mg Tablet at ৳ 25.00 per unit.

What is FeUP 210 FC 1000 mg Tablet?

FeUP 210 FC is an oral iron preparation from Advanced Chemical Industries PLC. Each tablet contains Ferric Citrate at a strength of 1000 mg. Ferric Citrate is used in adults with chronic kidney disease, both to help control serum phosphorus levels in people on dialysis and to treat iron deficiency anemia in people not on dialysis. Because it acts on iron and phosphate in the body, it is meant to be used under medical supervision, with the doctor deciding the dose and course for each person.

Uses of FeUP 210 FC

FeUP 210 FC is used in adults with chronic kidney disease. In people on dialysis, it helps control serum phosphorus levels by binding phosphate in the gut. In people not on dialysis, it is used to treat iron deficiency anemia. It is not a general tonic and should be used only when a doctor has assessed the person and confirmed that it is appropriate.

How to use FeUP 210 FC

FeUP 210 FC is a tablet taken by mouth, usually with meals as directed by the doctor. Swallow it as advised. The doctor decides the dose, how often it is taken, and how long the course lasts, and may adjust these over time based on how the person responds. Do not change the dose yourself. If you miss a dose or are unsure how to take it, ask your doctor or pharmacist.

Side effects of FeUP 210 FC

Common side effects include discolored feces, diarrhea, constipation, nausea, vomiting, cough, abdominal pain and high potassium levels. Some people may notice changes in iron stores, so the doctor may check iron parameters. Tell your doctor or pharmacist if you notice any side effect, if it bothers you, or if it does not go away. Do not stop or change the medicine on your own without medical advice.

Safety and precautions

FeUP 210 FC is not for people with iron overload syndromes. Iron absorption from Ferric Citrate can raise iron stores, especially if intravenous iron is also used, so the doctor may check iron parameters before and during treatment. There are no available data on use in pregnancy or breastfeeding, so pregnant or breastfeeding women should ask a doctor first. Anyone with kidney disease, other health conditions, or who takes other medicines should speak to the doctor before starting it.

Frequently asked questions

What does the tablet form and 1000 mg strength mean?

FeUP 210 FC is supplied as a tablet, which is a solid form taken by mouth. The 1000 mg strength describes how much Ferric Citrate each tablet contains. The doctor decides how the tablet is used and the course of treatment.

What is FeUP 210 FC used for and what kind of medicine is it?

It is an oral iron preparation used in adults with chronic kidney disease. In people on dialysis it helps control serum phosphorus levels, and in people not on dialysis it is used to treat iron deficiency anemia. A doctor decides whether it suits a person.

What does the generic name Ferric Citrate mean?

Ferric Citrate is the generic name of the active ingredient in FeUP 210 FC. It is an iron-based compound that acts on phosphate and iron in the body. The generic name identifies the medicine itself, while FeUP 210 FC is the brand name.

Can anyone take FeUP 210 FC?

No. It is not for people with iron overload syndromes, and it is used in adults with chronic kidney disease under medical supervision. Pregnant or breastfeeding women should ask a doctor first, as human data are not available. The doctor decides if it is suitable.

Indications

Ferric Citrate is a phosphate binder indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. Ferric Citrate is an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis.

Pharmacology

Hyperphosphatemia in chronic kidney disease on dialysis: Ferric iron binds dietary phosphate in the GI tract and precipitates as ferric phosphate. This compound is insoluble and is excreted in the stool. By binding phosphate in the GI tract and decreasing absorption, ferric citrate lowers the phosphate concentration in the serum.

Iron deficiency anemia in chronic kidney disease not on dialysis: Ferric iron is reduced from the ferric to the ferrous form by ferric reductase in the GI tract. After transport through the enterocytes into the blood, oxidized ferric iron circulates bound to the plasma protein transferrin, and can be incorporated into hemoglobin.

Dosage & Administration

Hyperphosphatemia in chronic kidney disease on dialysis:
  • Starting dose is 2 tablets orally 3 times per day with meals.
  • Adjust dose by 1 to 2 tablets as needed to maintain serumphosphorus at target levels, up to a maximum of 12 tablets daily. Dose can be titrated at 1-week or longer intervals.
Iron deficiency anemia in chronic kidney disease not on dialysis:
  • Starting dose is 1 tablet orally 3 times per day with meals.
  • Adjust dose as needed to achieve and maintain hemoglobin goal, up to a maximum of 12 tablets daily.

Interaction

When clinically significant drug interactions are expected, consider separation of the timing of administration. Consider monitoring clinical responses or blood levels of the concomitant medication.

Contraindications

Ferric Citrate is contraindicated in patients with iron overload syndromes.

Side Effects

Most common adverse reactions (incidence ≥5%) are discolored feces, diarrhea, constipation, nausea, vomiting, cough, abdominal pain, and hyperkalemia.

Pregnancy & Lactation

There are no available data on Ferric Citrate use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. There are no human data regarding the effect of Ferric Citrate in human milk, the effects on the breastfed child, or the effects on milk production.

Precautions & Warnings

Iron absorption from Ferric Citrate may lead to excessive elevations in iron stores. Increases in serum ferritin and transferrin saturation (TSAT) levels were observed in clinical trials. In a 56-week safety and efficacy trial evaluating the control of serum phosphate levels in patients with chronic kidney disease on dialysis in which concomitant use of intravenous iron was permitted, 55 (19%) of patients treated with Ferric Citrate had a ferritin level >1500 ng/mL as compared with 13 (9%) of patients treated with active control. Assess iron parameters (e.g., serum ferritin and TSAT) prior to initiating Ferric Citrate and monitor iron parameters while on therapy. Patients receiving intravenous iron may require a reduction in dose or discontinuation of intravenous iron therapy.

Overdose Effects

No data are available regarding overdose of Ferric Citrate in patients. In patients with chronic kidney disease, the maximum dose studied was 2,520 mg ferric iron (12 tablets of Ferric Citrate) per day. Iron absorption from Ferric Citrate may lead to excessive elevations in iron stores, especially when concomitant intravenous iron is used.

Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Alternative brands of Ferric Citrate

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.